Loading clinical trials...

Electrostimulation Study for Ocular Graft vs. Host Disease | Clinical Trials | Clareo Health

RECRUITINGNA

Electrostimulation Study for Ocular Graft vs. Host Disease

Pilot Trial of Non-invasive Electrostimulation in Chronic Ocular Graft-vs-Host Disease

NCT07166848•Zhonghui K. Luo, MD, PhD

Summary

This trial is testing to see if electrostimulation treatment (ET) will be effective in treating those with ocular Graft vs. Host Disease.

Detailed Description

The trial is to test whether transcutaneous electrical stimulation (TES) may be an effective new type of non-invasive treatment for patients who are diagnosed with chronic ocular Graft-vs-Host Disease. Such a treatment can potentially decrease the need for the patients to apply eye drops frequently, repair the damage caused by chronic ocular Graft-vs-Host Disease, and improve the comfort of the eyes naturally.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of chronic ocular graft vs. host disease (oGVHD) (ICCGVHD criteria probable or definite)
•OSDI score of 22 or higher
•NEI corneal staining score (or modified NEI score) of 2 or higher.

Exclusion Criteria

•Patients with any open wound on the eyelid.
•Patient with any active cornea ulcer, dacryocystitis, hordeolum, filamentary keratitis, uveitis, retinal detachment, uncontrolled glaucoma or other active pathology per PI's discretion.
•Patient with a pacemaker or ICD.
•Patient currently pregnant or with a potential to be pregnant during the study.
•Patient undergoing any ocular surgical procedure (including intravitreal injections) within the past 3 months.
•Patient undergoing any systemic surgical procedures within 2 months.
•Patient undergoing any non-surgical eyelid procedure such as punctal plugs or punctal cautery within 1 month of study initiation.
•Patients on cytotoxic agents, drugs that inhibit peripheral nerve regeneration (i.e. Gabapentin, Nicotine), radiation therapy, or any other therapy per PI's discretion.
•Patients undergoing immunosuppression regimen change within 1 month of study initiation and/or during the study period.
•Patient who wears contact lens of any kind

Locations (1)

Massachusetts Eye and Ear - Longwood Campus

Boston, Massachusetts, United States

Key Dates

Start Date

November 30, 2025

Primary Completion Date

November 30, 2028

Completion Date

November 30, 2029

Last Updated

December 17, 2025

Enrollment

ESTIMATED participants

Conditions

Chronic Ocular Graft-versus-host Disease

Interventions

Electrodes with Currents

DEVICE

Electrodes without Currents

DEVICE

Contacts

Michael Cheung, MSc, CCRP

CONTACT

6175736060 mcheung0@meei.harvard.edu

A Study of Stem Cells Lenses in the coGVHD Subjects

NCT06952114

Chronic Ocular Graft-versus-host Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions